Page 54 - Pharma Sector

Huge scope for Indian pharma as FDA eases drug scrutiny over shortage in US

Injectibles account for 60% of crunch; most plants under American regulator's lens the past two months have now received positive outcomes

Pharma traders protest govt's move to add e-pharmacy links to Aarogya Setu

The organisation today alleged that the NITI Aayog has added links to four e-pharmacy players

Indian drug makers gear up to make Gilead's remdesivir for Covid-19 therapy

Domestic players will be free to price it; Dutch firm Mylan also to make the drug in India; no royalty for Gilead as yet

Price drives Indian pharmaceutical market growth to five-year high in FY20

Ipca's Zerodol brand and its multiple variants used in treating pain and inflammation are an example of how this trend is playing out

Industry in Ahmedabad face first day jitters of complete lockdown

The first day impact has been more on the pharma especially in the wake of 26 workers at Cadila Pharmaceuticals Ltd.'s facility in Ahmedabad testing positive for COVID-19

Letter to BS: Pharma industry, pharmacists also deserve appreciation

India has the potential to develop an antidote to Covid-19

Markets at inflexion point; analysts bullish on consumer, telecom, pharma

The recovery seen in the markets from their March 2020 lows has been quite sharp, with the S&P BSE Sensex and the Nifty50 indices gaining 27.61 per cent and 27.18 per cent, respectively since then

Diversified model, US outlook to help Dr Reddy's stock trade better

The company has multiple growth engines given its focus on India/emerging markets and limited competition products in the US

Pharma traders seek IT rule exemption as retailers pay stockists in cash

They fear scrutiny by tax authorities at a later date, assure that the relaxation will not be misused

Pharma shares rally; Alembic, Sun Pharma, Laurus Labs hit 52-wk highs

Strides Pharma Science, Alkem Laboratories, Ajanta Pharma, Lupin, Ipca Laboratories, Jubilant Life Sciences and FDC were up in the range of 5 per cent to 10 per cent on the BSE

Pharma traders oppose Medlife-Uber partnership to deliver medicines

Uber, in a press release, had said that the partnership was aimed at ensuring that essential needs are fulfilled right in the safety of customers' homes

From pharmaceuticals to aviation: The impact of coronavirus crisis

Indian airline operators and airports have been the first and the most adversely affected sector.

Covid-19 impact: Pharma players join hands to ensure smooth production

Combined capacity utilisation at all-India level is 60-70% - higher than in most other industries

Govt's crucial move towards nursing 5 sectors back to health amid lockdown

These five sectors are textiles, chemicals, electronics, steel and pharmaceutical

Covid-19: India partially lifts ban on export of paracetamol and HCQ

HCQ is the same drug that US President Donald Trump had sought from India and warned of retaliation if India did not supply the drug

Aurobindo terminates $900-million Sandoz product acquistion deal

A mutual decision to cancel the agreement was taken as approval from US Federal Trade Commission was not obtained within anticipated timelines

Pharma major Cipla gets USFDA nod for generic oral acid reflux drug

According to IQVIA, Nexium and its generic equivalents had US sales of around $70 million for the 12 months ended November 2019

Indian Pharmaceutical Alliance says it is committed to help fight Covid-19

Towards this, the alliance and its members are working with the governments and other public agencies, pharma industry associations and all other key stakeholders, it said in a statement

Ipca Labs, Lupin: Pharma stocks show healthy trend, bottom could be near

Whenever the Nifty pharma index has dipped below oversold territory on the Relative Strength Index (RSI), it has seen a stable rise.

Accord Group enters pharma business, targets sales in 18 states

The company has invested around Rs 600 crore into a manufacturing facility in Chennai and plans to invest around Rs 1,500 crore by March 2022, for R&D, acquisitions and others as part of expansion